X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (584) 584
campath-1h (519) 519
alemtuzumab (472) 472
male (327) 327
antibodies, monoclonal, humanized (310) 310
female (293) 293
index medicus (288) 288
middle aged (283) 283
antibodies, monoclonal - therapeutic use (258) 258
hematology (244) 244
transplantation (242) 242
adult (241) 241
antibodies, neoplasm - therapeutic use (210) 210
oncology (184) 184
aged (179) 179
treatment outcome (159) 159
therapy (158) 158
antineoplastic agents - therapeutic use (138) 138
immunology (137) 137
alemtuzumab campath-1h (127) 127
surgery (123) 123
leukemia, lymphocytic, chronic, b-cell - drug therapy (110) 110
fludarabine (105) 105
chronic lymphocytic-leukemia (104) 104
immunosuppressive agents - therapeutic use (101) 101
rituximab (98) 98
antibodies, monoclonal - adverse effects (91) 91
cd52 antigen (91) 91
antibodies, neoplasm - adverse effects (85) 85
monoclonal antibodies (85) 85
adolescent (83) 83
antibodies, monoclonal - administration & dosage (82) 82
antibodies, neoplasm - administration & dosage (79) 79
immunosuppression (68) 68
chronic lymphocytic leukemia (67) 67
immunotherapy (67) 67
antibodies, monoclonal, humanized - therapeutic use (64) 64
cd52 (64) 64
monoclonal-antibody (64) 64
retrospective studies (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (58) 58
care and treatment (58) 58
renal-transplantation (58) 58
animals (55) 55
kidney transplantation (54) 54
recipients (53) 53
follow-up studies (52) 52
risk factors (52) 52
t cells (52) 52
antibody (51) 51
health aspects (51) 51
stem-cell transplantation (51) 51
time factors (49) 49
transplantation, homologous (49) 49
cll (48) 48
graft rejection - prevention & control (48) 48
vidarabine - analogs & derivatives (48) 48
antigens, cd - immunology (47) 47
child (47) 47
recurrence (47) 47
chemotherapy (46) 46
disease (46) 46
kidney-transplantation (46) 46
leukemia (46) 46
monoclonal antibody (46) 46
remission induction (45) 45
aged, 80 and over (44) 44
induction (44) 44
leukemia, lymphocytic, chronic, b-cell - therapy (44) 44
young adult (44) 44
antibodies, monoclonal - pharmacology (43) 43
antibodies, neoplasm - pharmacology (43) 43
t-cells (43) 43
tacrolimus (43) 43
campath‐1h (42) 42
phase-ii trial (42) 42
antineoplastic agents - adverse effects (41) 41
kidney transplantation - immunology (41) 41
lymphocytes (41) 41
tolerance (41) 41
bone-marrow-transplantation (40) 40
drug therapy (40) 40
multiple sclerosis (40) 40
antigens, neoplasm - immunology (39) 39
clinical trials as topic (39) 39
glycoproteins - immunology (39) 39
non-hodgkins-lymphoma (39) 39
survival analysis (39) 39
lymphoma (38) 38
versus-host-disease (38) 38
antibodies (37) 37
cancer (37) 37
flow cytometry (37) 37
lymphocyte depletion (37) 37
research (37) 37
graft rejection - immunology (36) 36
drug therapy, combination (35) 35
expression (35) 35
kidneys (35) 35
prognosis (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (684) 684
German (8) 8
Russian (2) 2
French (1) 1
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEUROLOGY, ISSN 0028-3878, 04/2012, Volume 78, Issue 14, pp. 1069 - 1078
Objective: To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon beta-1a in early, active relapsing-remitting... 
CAMPATH-1H | THERAPEUTIC LYMPHOCYTE DEPLETION | MULTIPLE-SCLEROSIS | CLINICAL NEUROLOGY
Journal Article
Lancet, The, ISSN 0140-6736, 11/2012, Volume 380, Issue 9856, pp. 1829 - 1839
Journal Article
JOURNAL OF NEUROLOGY, ISSN 0340-5354, 01/2006, Volume 253, Issue 1, pp. 98 - 108
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte... 
RHEUMATOID-ARTHRITIS | INTERFERON TREATMENT | CONTROLLED-TRIAL | THYROID-FUNCTION | multiple sclerosis | cerebral atrophy | PROGRESSIVE MS | Campath-1H | CLINICAL-COURSE | CLINICAL NEUROLOGY | AUTOIMMUNE-DISEASES | NITRIC-OXIDE | MONOCLONAL-ANTIBODY THERAPY | ANTITHYROID ANTIBODIES
Journal Article
Transplantation Proceedings, ISSN 0041-1345, 12/2018, Volume 50, Issue 10, pp. 3739 - 3747
Background and objectives: Heart and lung transplantation is a high-risk procedure, requiring intensive immunosuppressive therapy for preventing organ... 
SURGERY | CAMPATH-1H | CD52 | IMPACT | IMMUNOSUPPRESSION | TIME | OUTCOMES | IMMUNOLOGY | TACROLIMUS | BASILIXIMAB INDUCTION | TRANSPLANTATION
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 08/2009, Volume 9, Issue 8, pp. 1835 - 1845
Alemtuzumab is a monoclonal antibody that depletes T and B cells and is used as induction therapy for renal transplant recipients. Without long-term... 
BAFF | Campath-1H | Alemtuzumab | sirolimus | renal transplant | Campath‐1H | Renal transplant | Sirolimus | B-LYMPHOCYTE STIMULATOR | SURGERY | CAMPATH-1H INDUCTION | SYSTEMIC-LUPUS-ERYTHEMATOSUS | PRIMARY SJOGRENS-SYNDROME | TRANSPLANTATION | OVEREXPRESSION | CELL ACTIVATING FACTOR | REGULATORY T-CELLS | ALLOGRAFT RECIPIENTS | IMMUNOSUPPRESSIVE DRUGS | APRIL | Antibodies, Neoplasm - therapeutic use | Kidney Transplantation - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Case-Control Studies | Antigens, CD - metabolism | Transmembrane Activator and CAML Interactor Protein - metabolism | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Neoplasm - pharmacology | T-Lymphocytes - drug effects | Adult | Female | B-Lymphocytes - pathology | T-Lymphocytes - pathology | Graft Rejection - pathology | Tumor Necrosis Factor Ligand Superfamily Member 13 - blood | Antibodies, Monoclonal - pharmacology | Graft Rejection - prevention & control | Lectins, C-Type | Antigens, Differentiation, T-Lymphocyte - metabolism | B-Lymphocytes - drug effects | B-Cell Maturation Antigen - metabolism | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | Aged | B-Cell Activating Factor - blood | Care and treatment | Messenger RNA | Kidneys | Lymphocytes | Analysis | Organ transplant recipients | Transplantation | Public health
Journal Article
Transplantation Proceedings, ISSN 0041-1345, 12/2018, Volume 50, Issue 10, pp. 3723 - 3731
Heart and lung transplantation is a high-risk procedure requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a... 
SURGERY | CAMPATH-1H | CD52 | PHARMACODYNAMICS | TIME | IMMUNOLOGY | BASILIXIMAB INDUCTION | TRANSPLANTATION | IMPACT | PHARMACOKINETICS | RECEIVING ALEMTUZUMAB | OUTCOMES | TACROLIMUS
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2018, Volume 73, Issue 5, pp. 615 - 619
Alemtuzumab, a humanized monoclonal antibody that targets CD52 antigens on lymphocytes and monocytes, has shown efficacy in preventing relapse in... 
kidney biopsy | alemtuzumab | Drug-induced thrombotic microangiopathy | microangiopathic hemolytic anemia (MAHA) | multiple sclerosis | case report | acute kidney injury | thrombotic microangiopathy (TMA) | UROLOGY & NEPHROLOGY | CAMPATH-1H | MECHANISMS | BASEMENT-MEMBRANE DISEASE
Journal Article